WO
WOLF.V Grey Wolf Animal Health Corp.
- Market cap
- CAD 58.2M
- P/E
- 33.6x
- P/B
- 1.83x
- ROE
- 4.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is WOLF.V undervalued?
Graham numberWOLF.V trades 65.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Grey Wolf Animal Health Corp. fundamental analysis
No fundamental analysis for Grey Wolf Animal Health Corp. yet.
Grey Wolf Animal Health Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Grey Wolf Animal Health Corp.
Grey Wolf Health Corp. operates as an animal health and wellness company in Canada. The company operates in two segments, Animal Health Business Unit and Pharmacy Business Unit. It engages in the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics, as well as offers pharmaceuticals for the human and animal health markets. The company provides dexmedetomidine hydrochloride oromucosal gel under the SILEO name; sedat…
Full company profileGrey Wolf Animal Health Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Grey Wolf Animal Health Corp. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 13.1M | 22.6M | 25.4M | 26.8M | 35.8M | 38.7M |
| Gross Profit | - | 7.15M | 11.6M | 12.8M | 13.8M | 19.1M | 21.2M |
| Operating Income | - | 70.4K | -356K | 1.55M | 1.91M | 4.06M | 3.81M |
| EBITDA | - | - | 9.99M | 3.15M | 3.58M | 6.85M | 6.60M |
| Net Income | - | -969K | 2.54M | 610K | 705K | 1.66M | 1.30M |
| EPS | - | -0.03 | 0.08 | 0.02 | 0.02 | 0.05 | 0.04 |
| Balance Sheet | |||||||
| Total Assets | - | 36.2M | 39.3M | 41.4M | 65.6M | 64.5M | 64.8M |
| Total Liabilities | - | 32.2M | 15.1M | 16.3M | 36.8M | 34.0M | 33.1M |
| Shareholders' Equity | - | 4.08M | 24.2M | 25.1M | 28.8M | 30.6M | 31.7M |
| Cash & Short-term Investments | - | 4.35M | 6.86M | 7.78M | 6.41M | 7.67M | 8.90M |
| Cash Flow | |||||||
| Operating Cash Flow | 596K | 2.14M | -710K | 2.43M | 1.75M | 3.83M | 4.41M |
| Capital Expenditure | 15.0K | 15.0K | 53.8K | 284K | 534K | 519K | 726K |
| Free Cash Flow | - | 2.12M | -764K | 2.15M | 1.21M | 3.31M | 3.68M |
| Ratios | |||||||
| ROE | - | -23.8% | 10.5% | 2.4% | 2.4% | 5.4% | 4.1% |
| ROA | - | -2.7% | 6.5% | 1.5% | 1.1% | 2.6% | 2.0% |
| Net Profit Margin | - | -7.4% | 11.2% | 2.4% | 2.6% | 4.6% | 3.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Grey Wolf Animal Health Corp. dividends
Grey Wolf Animal Health Corp. has not paid dividends in the last 6 fiscal years.
Who owns Grey Wolf Animal Health Corp.
- Insiders 12.75%
- Institutions 10.42%
- Public & others 76.84%
- Shares outstanding 34.6M
- Free float 26.5M
Grey Wolf Animal Health Corp. company profile
- Company name
- Grey Wolf Animal Health Corp.
- Ticker
- WOLF.V
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Diversified Consumer Services
- Fiscal year end
- December
- Address
- Bay Adelaide ? West Tower, Toronto, ON, Canada, M5H 2R2
- Website
- greywolfah.com
About Grey Wolf Animal Health Corp.
Grey Wolf Health Corp. operates as an animal health and wellness company in Canada. The company operates in two segments, Animal Health Business Unit and Pharmacy Business Unit. It engages in the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics, as well as offers pharmaceuticals for the human and animal health markets. The company provides dexmedetomidine hydrochloride oromucosal gel under the SILEO name; sedative analgesic and reversing agents for companion animals under the SEDAJECT and ATAJECT names; prescription drugs under the THYRO-TABS CANINE name; and wound care products, including medical grade tubes, viscose net dressings, alginate dressing, absorbent foam dressing, superabsorbent dressing, and silicone perforated tapes, as well as medical pet shirt protective wear products, such as pet shirt, pets boot, head cover, and leg sleeves. It also offers disposables comprising syringes, needles, and IV catheters; and nutraceuticals, as well as equine health products. The company was formerly known as Grey Wolf Animal Health Corp. and changed its name to Grey Wolf Health Corp. in June 2026. The company is headquartered in Toronto, Canada.
Grey Wolf Animal Health Corp. management
5- Ms. Angela CechettoCEO & Secretary
- Dr. Ian SandlerFounder, Chief Veterinary Medical Officer & Director
- Mr. Kevin S. Palmer C.A., CPA, M.B.A.Chief Financial Officer
- Mr. Brandon Mair-WrenVice President of Operations
- Ms. Susan BodnerVice President of Sales & Marketing